Search - tctmd.com

Displaying 1 - 8 of 8

Sort: Relevancy | Date

Presentation THT 2025

Overview of Residual Risk and Pathophysiological Targets for Devices to Treat Chronic HF

Presenter: Marat Fudim

February 12, 2025

Presentation THT 2025

Residual Risk in HFpEF and the Potential Role of Interatrial Shunts

Presenter: Javed Butler

February 11, 2025

Presentation TCT 2024

PRO: Time is Now: Targeting Acute Inflammation and Residual Inflammatory Risk

Presenter: Vijay Kunadian

October 29, 2024

Presentation TCT 2024

TCT 1021: Remaining Cholesterol Crystals Against Lipid-Lowering Therapy as a Residual Risk

Presenter: Ryo Hikida

October 29, 2024

Presentation TCT 2024

Modern GDMT for HFrEF: Great but Significant Residual Risks Remain

Presenter: Javed Butler

October 28, 2024

Presentation TCT 2023

TCT 249: Remnant Cholesterol as a Residual Risk in Patients with Atherosclerotic Cardiovascular Disease under Moderate-intensity Statin with Ezetimibe Combination Therapy or High-intensity Statin Monotherapy

Presenter: Jung-Hee Lee

October 25, 2023

Presentation THT 2023

Assessing the Residual Risk: What Gaps Should New Technologies Fill?

Presenter: Javed Butler

March 20, 2023

Presentation TCT 2012

What Is Optimal Medical Management for Carotid Disease, and What Residual Risk Remains Without Revascularization?

Presenter: Michael Jaff

October 22, 2012

Advertisement

Overview of Residual Risk and Pathophysiological Targets for Devices to Treat Chronic HF

Residual Risk in HFpEF and the Potential Role of Interatrial Shunts

PRO: Time is Now: Targeting Acute Inflammation and Residual Inflammatory Risk

TCT 1021: Remaining Cholesterol Crystals Against Lipid-Lowering Therapy as a Residual Risk

Modern GDMT for HFrEF: Great but Significant Residual Risks Remain

TCT 249: Remnant Cholesterol as a Residual Risk in Patients with Atherosclerotic Cardiovascular Disease under Moderate-intensity Statin with Ezetimibe Combination Therapy or High-intensity Statin Monotherapy

Assessing the Residual Risk: What Gaps Should New Technologies Fill?

What Is Optimal Medical Management for Carotid Disease, and What Residual Risk Remains Without Revascularization?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content